Lymphoma Therapy

High-dose chemo with CD34+-APBSCT effective against nasal NK/T-cell lymphoma

Published in Blood Weekly, February 19th, 2004

High-dose chemotherapy with CD34+-APBSCT can be used to effectively treat nasal NK/T-cell lymphoma.

According to published research from Japan, the prognosis for patients with this malignancy "with cutaneous involvement especially is morbid despite intensive chemotherapy and radiotherapy."

K. Koizumi and coauthors at Hokkaido University "treated a 52-yr-old Japanese woman with cutaneous dissemination of nasal NK/T-cell lymphoma."

"Six cycles of chemotherapy, irradiation to skin lesion were administered and complete remission (CR) was attained," they explained. "High-dose chemotherapy (HDC; etoposide 750 mg/m² x 2 d,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry